Royalty Report: Drugs, Therapeutic, cardiac – Collection: 25908

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Therapeutic
  • cardiac
  • Pharmaceuticals
  • Cancer
  • Biotechnology
  • Tobacco
  • Nicotine
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 25908

License Grant
The Licensor will grant the Licensee a non-exclusive license for all patents related to heart muscle regeneration and angiogenesis for the life of the patents. Sublicensing of these patents by the Licensee is not allowed.
License Property
Angiogenesis is a physiological process involving the growth of new blood vessels from pre-existing vessels.  Therapeutic angiogenesis is the application of specific compounds which may inhibit or induce the creation of new blood vessels in the body in order to combat disease.
Field of Use
The rights granted apply to heart muscle.

IPSCIO Record ID: 227271

License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.

The agreement is exclusive except for the non-exclusive license granted to the U.S. government

License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.

2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth

2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo

Anti-Angiogenesis for the Treatment of Cancer

In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.

Field of Use
Field of Use shall mean any field of use.

IPSCIO Record ID: 3661

License Grant
Whereby the founder of the Company granted to us a non-revocable exclusive perpetual right to use, modify, add to, practice and sell the results of the founder of the Company’s German clinical trials.
License Property
We are a biopharmaceutical company focused on developing new drugs for the treatment of cardiovascular diseases where the growth of new blood vessels can improve the outcome for patients with these diseases. The active pharmaceutical ingredient (API) in our drug candidates is FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart and other tissues and organs with an impaired vascular system, a process referred to in the scientific community as angiogenesis.
Field of Use
The rights apply to cardiovascular diseases.

IPSCIO Record ID: 5858

License Grant
The Licensor has granted the Licensee a non-revocable and exclusive worldwide license including the right to sublicense to third parties to the patents necessary to develop and commercialize drug candidates in which Cardio Vascu-Grow is the active ingredient. As a part of that agreement, Licensor will provide technical development services to us for the development and regulatory approvals of our drug candidates, including but not limited to, lab work, testing and production of our drug candidates in which Cardio Vascu-Grow is the active ingredient for clinical trials, all as directed by us.
License Property
We are working closely with an affiliated company, Cardio, pursuant to a joint patent and technology sharing agreement, to manufacture human fibroblast growth factor-1 (Cardio Vascu-Grow) for Cardio’s ongoing clinical trials.

Cardio Vascu-Grow Human Fibroblast Growth Factor-1 treat patients with advanced atherosclerotic disease of their coronary arteries. This treatment, which regenerates new blood vessels in the hearts of these patients.  Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low density (especially small particle) lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL), (see apoA-1 Milano).

Issued US Patents
1. U.S. 6,268,178 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;” and
2. U.S. 6,642,026 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.”
3. U.S. 6,773,899 entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides”;
4. U.S. 6,794,162, entitled “Phage-Dependent Super-Production of Biologically Active Protein and Peptides;”
Pending US Patent Applications 1.. U.S. 10/649,480 entitled “Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis;” published as US Patent Application No. US 2004/0115769

Field of Use
Cardio Vascu-Grow™ stimulates the growth of new blood vessels, a biological process termed “angiogenesis”. This growth factor is being tested in a wide variety of human diseases that would benefit from increased angiogenesis including coronary artery disease, stroke, and peripheral vascular disease of the legs and wound healing.

IPSCIO Record ID: 227272

License Grant
Licensor Institute, a nonprofit American medical research facility, grants an exclusive, worldwide license, including the right to sublicense, to Licensors Technology and under Licensors Patent Rights, to make, to have made, to import, to use, to offer for sale, and to sell Licensed Products in the Field.

This agreement also contains a non-exclusive grant back from Licensee to Licensor.

License Property
The patents are for Methods and Compositions for Enhancing Angiogenesis, Methods and Compositions for Modulation T-cell Activation and Uses thereof, and, Methods for Detecting Vasculopathies and Tumors.

Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.

Field of Use
The term Field shall mean human therapeutic and diagnostic applications and shall specifically exclude any Agricultural Product.

Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.

IPSCIO Record ID: 4702

License Grant
The Company entered into an exclusive license agreement with the University to assist in the development of the Nicotine Receptor Agonist technology.
License Property
Nicotine Receptor Agonist technology promotes new growth of blood vessels (known as angiogenesis or vasculogenesis), and has applications in the treatment of heart disease, stroke, limb circulatory disease, and wound healing.

IPSCIO Record ID: 227270

License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to make, use and sell and to have made, have sold and sublicense the Products; and
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any SubLicensee agrees to be bound by the terms and conditions of this Agreement applicable to SubLicensee.  

The exclusive license means exclusive except for the non-exclusive license granted to the U.S. government.

License Property
The patents are for Identification of a Fragment of a Metalloproteinase That Potentially Inhibits Angiogenesis and Tumor Growth in Vivo, and, Identification of a Fragment of a Metalloproteinase That Stimulates Tumor Growth in Vivo.
Field of Use
The Field of Use shall mean any fields of use.

Angiogenesis, or the formation of new blood vessels, is necessary for the growth and spread of tumors. Licensee's antibodies and peptides bind to newly exposed sites on proteins, such as collagen, during the remodeling of the extracellular matrix, which occurs during angiogenesis.  Objective is to establish our position as a leader in the development and marketing of specific active immunotherapy and other biological products for the treatment and control of cancer.

IPSCIO Record ID: 28258

License Grant
The Company entered into an exclusive license agreement with a University to assist in the development of the Nicotine Receptor Agonist technology.  The Licensee has exclusive worldwide licensing rights to develop, manufacture, use and sell products incorporating nicotine and nicotine agonists for therapeutic angiogenesis.
License Property
Nicotine Receptor Agonist technology promotes new growth of blood vessels (known as angiogenesis or vasculogenesis), and has applications in the treatment of heart disease, stroke, limb circulatory disease, and wound healing.

IPSCIO Record ID: 368507

License Grant
The Licensor, an individual, hereby grants to Licensee an exclusive license to practice under the Licensed Patents and use the licensed information, with the right to grant sublicenses, to make, have made, use, sell, have sold, offer to sell, import or export Licensed Products within the field in the licensed territory (the License).
License Property
The intellectual property portfolio for 2NTX-99 includes an issued U.S. patent and a pending Patent Cooperative Treaty submission relating to its composition of matter, multiple methods of manufacturing, and method of use in treating a variety of atheroclerotic-thrombotic pathological conditions.

U.S. Patent 6,525,078 B1 dated February 24, 2003 entitled “Compound for the Treatment of Athreosclerotic-Thrombotic Pathological Conditions.

Field of Use
2NTX-99 has potential utility in a range of atherosclerotic, thrombotic and microvascular diseases.

Atherosclerosis is thickening or hardening of the arteries caused by a buildup of plaque in the inner lining of an artery.
Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. It prevents blood from flowing normally through the circulatory system. Blood clotting, also known as coagulation, is the body's first line of defense against bleeding.
Coronary disease (MCD) is the narrowing of the small blood vessels that branch off the coronary arteries and send oxygen-rich blood to the heart muscle. This decreases the amount of blood that goes to the heart muscle, which leads to chest pain (angina).

IPSCIO Record ID: 328338

License Grant
Licensor grants the Licensee of Japan the right and license, with no right to sublicense except as provided under the Licensor Patents and the Know-How, solely to use the Licensed Compounds to conduct Development and to import, use, and sell Products solely for use in the Field within the Territory.

For Other Indications for Licensed Compounds, Licensor grants a right of first refusal to obtain licenses to use Licensed Compounds for other applications or indications outside the Field.

For Rights to Related Compounds. Licensor grants the right to include within the license rights granted under the License specific Related Compounds.

The Parties are to develop  and  commercialize LR-3280 and certain related oligonucleotide compounds in Japan and certain other countries in Asia for the prevention or treatment of restenosis in any blood vessel  following an angioplasty or similar procedure,  and Licensor will supply Licensee quantities of product containing such compounds for clinical use and commercial sale.

License Property
Licensor is engaged in research and  development of, among other things, oligonucleotides and oligonucleotide  analogs that may be useful for therapeutic treatment of disease conditions.   Licensor is presently developing  one such oligonucleotide compound, identified as LR-3280 targeted to c-myc mRNA, as a pharmaceutical product for the prevention or treatment of restenosis in any blood vessel following an angioplasty or similar procedure.

The patents subject matter includes but is not limited to
–  Method of inhibition smooth muscle cell proliferation by treating with c-myc antisense;
–  Method of treating restenosis by administrating c-myr antisense;
–  Method of Inhibiting collagen synthesis by treating with c-myr antisense;
–  Method of treating vascular grafts to reduce stenosis by applying c-myr antisense to graft; and,
–  Pharmaceutical compositions for the above methods.

Licensed Compounds means the oligonucleotide compound identified by Licensor as LR-3280, and any other phosphorothioated oligonucleotidc compounds that now or hereafter are owned or Controlled by Licensor or its Affiliates and that specifically target the mRNA transcribed from the c-myc gene, or contain four deoxyguanosine nucleotides in a row and are developed by Licensor for use in the Field.

Clinical Trial Product means a product,  appropriate for use in clinical trials, containing a Licensed  Compound or placebo, as applicable, in the formulation as determined by Licensee.

Field of Use
Field means the prevention or treatment of restenosis in humans in any blood vessel by use of a Licensed Compound delivered to the affected blood vessel via a Delivery Means following any stenosis-reducing medical procedure that is Transient in nature and that is intended to reduce the obstruction of the blood flow in a stenosed vessel (including without limitation percutaneous transluminal angioplasty, percutaneous transluminal coronary angioplasty and angioplasty involving placement of an intravascular stent).

Restenosis is the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.